ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned a consensus recommendation of “Buy” from the nine analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $79.75.

Several equities analysts have recently commented on the company. StockNews.com downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 8th. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They set a “buy” rating and a $80.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $68.12 on Friday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $70.00. The firm’s 50 day simple moving average is $62.34 and its two-hundred day simple moving average is $59.07. The company has a market capitalization of $1.48 billion, a P/E ratio of -123.85 and a beta of 0.49.

Insider Activity at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Meredith Cook sold 400 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. The trade was a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock valued at $191,776 over the last ninety days. 12.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its holdings in shares of ANI Pharmaceuticals by 3.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 250,346 shares of the specialty pharmaceutical company’s stock worth $14,936,000 after purchasing an additional 8,869 shares during the last quarter. FMR LLC raised its holdings in shares of ANI Pharmaceuticals by 27.5% during the third quarter. FMR LLC now owns 18,401 shares of the specialty pharmaceutical company’s stock valued at $1,098,000 after acquiring an additional 3,972 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares in the last quarter. HighTower Advisors LLC purchased a new position in shares of ANI Pharmaceuticals in the third quarter worth about $222,000. Finally, Hotchkis & Wiley Capital Management LLC purchased a new position in ANI Pharmaceuticals in the 3rd quarter worth approximately $3,107,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.